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Synthesis of F3CO- and F2HCO-heterocyclic building blocks; preparation and evaluation of 
biological properties of novel analogues of Imidacloprid and Thiacloprid 
 
Highlights: 
Ø F3CO- and F2HCO-heterocyclic building blocks 
Ø Difluoromethylation of hydroxylated heterocycles 
Ø F3CO- and F2HCO-analogues of Imidacloprid & Thiacloprid 
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Abstract 
 
The preparation of F3CO- and F2HCO-analogues of Imidacloprid and Thiacloprid and the 
evaluation of their biological activity have been performed. For this purpose, a first synthetic 
approach allowed the preparation of a desired F3CO-containing key intermediate. To allow a 
facile access to the second F2HCO-containing key intermediate, the difluoromethylation of 
hydroxylated N-based heterocycles has been developed using difluoromethyl triflate (a liquid 
non-ODS reagent) under air in aqueous conditions and with very short reaction time. The 
broad diversity of compatible heterocycles includes a large series of substituted hydroxy-
pyridines, but also -pyrazoles, -pyrazine, -pyridazine, and -quinolines. The couplings of both 
key intermediates with the required 4,5-dihydro-N-nitro-1H-imidazol-2-amine and [N(Z)]-N-
2-thiazolidinylidene-cyanamide were successfully achieved using literature conditions. This 
work enables the preparation of valuable building blocks, which could lead to the discovery 
of new bioactive entities. 
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1. Introduction 
 
Since some years ago, the electron-withdrawing trifluoromethoxy (F3C-O) and 
difluoromethoxy (F2HC-O) groups are becoming more and more important in modern crop 
protection but also in pharmaceutical chemistry[1-6], because they can protect an aromatic 
ring system against oxidative (or electrophilic) attacks. An increased stability towards 
degradation is observed for active ingredients or fragments containing this special substitution 
pattern. Based on its electronic properties, which are close to the halogen atoms chlorine and 
fluorine[7], the F3C-O group has been referred as a super-[8] or a pseudo[9]-halogen. The 
fluorinated carbon adjacent to an oxygen atom increases lipophilicity as shown by the high 
value of the F3C-O hydrophobic substituent parameter[10-12]. It appears that the F3C-O 
substituent is far more lipophilic (p = +1.04) than the halogens and lies between a F3C (p = 
+0.88) and a F3C-S (p = +1.44) group. It may thus replace advantageously a fluorine atom (p 
= +0.14) in most molecules with the benefit of increased lipid solubility. 
The trifluoromethoxy substituent can induce particular conformational changes due to its 
anisotropic character (in difference to the isotropic trifluoromethyl group)[13] and adopt an 
orthogonal orientation with respect to an arene plane, in contrast to the methoxy group, which 
normally lies in the plane of the arene[14, 15]. In fact, the electron density of the non-bonding 
p-orbitals at oxygen is very low. The electrons of the oxygen p-orbital are delocalized into the 
antibonding orbitals of the trifluoromethyl C–F bonds[16]. As a consequence, the oxygen 
non-bonding orbitals are not conjugated with the aromatic ring system; therefore the F3C-
group of F3C-O lies out of the arene plane, and the rotational barrier is significantly lower 
than that for a methoxy group[17-19]. This behaviour can be used to tune the binding affinity 
in drug-target complexes. The use of the F3C-O-motif in pharmaceuticals led to major 
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breakthroughs; Riluzole was the first drug approved for amylotropic lateral sclerosis 
treatment; Delamanid is included in the World Health Organization List for essential 
medicines as prodrug for tuberculosis treatment; Celikalim is a vasorelaxing agent protecting 
cardiac muscles. In addition, marketed agrochemicals bearing the F3CO-motif display various 
possible MoAs; Indoxacarb is a Voltage-gated sodium channel (VgSoCh) blocker; 
Thifluzamide is a fungicide (SDH Complex II inhibitor); Flurprimidol is Plant Growth 
Regulator (or PGR) (Figure 1). 
The difluoromethoxy group shares several key properties with its renowned trifluoromethoxy 
analogue (high electronegativity, excellent lipophilicity, specific electronic distribution, 
thermal/chemical stability), but is not as bulky and displays an additional H-bonding capacity. 
This combination of properties makes the F2CH-O-group more and more popular. It is found 
in medicinally relevant compounds that include enzyme inhibitors (e.g.: Roflumilast, a 
selective and long-acting phosphodiesterase-4 inhibitor, anti-HIV agents and antimicrobial 
agents). Pantoprazole is a nice example of F2CH-O-containing drug found in the top 100 
selling drugs in 2013, as well as several cardiovascular medications, such as Riodipine 
(Figure 1)[1]. Surprisingly, most of marketed drugs are commonly bearing an aryl-OCHF2 
motif, but no example is known with heteroaryl-OCHF2 motif. 
Difluoromethoxy compounds are less described in marketed agrochemicals; only several 
examples containing a F2CH-O-heteroaryl moiety are currently on the market: Diflumetorim 
is a fungicide (SDH Complex I inhibitor); Pyroxasulfone is a VLCFAs (Very Long Chain 
Fatty Acids) biosynthesis inhibitor; Flucythrinate, an insecticide acting as Voltage-gated 
sodium channel blocker, also contains this group (Figure 1)[2]. 
 
 
Figure 1. F3CO- and F2HCO-bearing drugs and agrochemicals. 
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These examples clearly illustrate the large potential of both F3CO- and F2HCO-substituents 
for the development of new bioactive ingredients. Therefore, we became interested in 
preparing new analogues of pyridine-containing neonicotinoid insecticides Imidacloprid and 
Thiacloprid, containing either 6-trifluoromethoxy- or 6-difluoromethoxy-pyridin-3-yl-methyl 
moieties. 
 
 
2. Results and discussion 
 
 Trifluoromethoxy-derivatives 
Our group was the first to report on the modular synthesis of a library of 
trifluoromethoxylated pyridines[17]. This approach has been applied in the synthesis of 
F3CO-analogues of Imidacloprid and Thiacloprid.  
According to our procedure, 2-chloro-6-hydroxypyridine was converted in situ into the 
corresponding chlorothionoformate and submitted to a chlorination with elemental chlorine in 
chloroform at room temperature yielding the corresponding trichloromethyl ether 1 in 60% 
yield (Scheme 1). Subsequent fluorination in the presence of antimony trifluoride and 
catalytic antimony pentachloride provided 2-chloro-6-trifluoromethoxypyridine 2 in 53% 
yield. Next, pyridine 2 was protected in the 3-position with a TMS group by metalation with 
lithium diisopropyl amide (LDA) and subsequent trapping with trimethylsilyl chloride 
(TMSCl). The nicotinic acid 4 was then prepared by metalation of 3 with lithium tetramethyl 
piperidide (LiTMP) followed by trapping with carbon dioxide and direct deprotection of the 
TMS group. Palladium-catalysed dechlorination to afford the 2-(trifluoromethoxy)nicotinic 
acid 5 was performed with 76% yield. The reduction of the acid into the corresponding 
primary alcohol was performed with 70% yield with BH3·THF. The expected chlorinated 
product 7 was obtained by an in situ mesylation-chlorination in 56% yield. This product was 
further coupled with 4,5-dihydro-N-nitro-1H-imidazol-2-amine or N-(4,5-dihydro-2-thiazolyl) 
cyanamide, to provide the two desired trifluoromethoxy analogues of Imidacloprid and 
Thiacloprid (8 and 9) in 38% and 74 % yield respectively (Scheme 1). 
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Scheme 1. Synthesis of F3CO-Imidacloprid (8) and Thiacloprid (9). 
 Difluoromethoxy-precursors 
The synthesis of F2HCO-compounds was reported either by the use of ozone-depleting 
CHF2Cl gas, or by means of many other difluorocarbene precursors. The generated 
difluorocarbene is reacted with an alkoxide/phenoxide to provide the corresponding F2HCO-
product. Elevated temperatures or poor functional group tolerance were sometimes important 
drawbacks of these approaches[20]. Hartwig reported a new approach for the preparation of 
difluoromethoxylated aromatics by means of a non-ODS-based reagent, namely 
difluoromethyl triflate (TfO-CHF2), which displays difluorocarbene reactivity[21]. This 
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desired product in 85% yield (Table 1, entry 8). Attempts to deviate from these conditions, in 
terms of solvent, base or amount of base could not provide any improvement (Table 1). 
Difluoromethyl triflate was prepared using Dilman’s procedure[22]. 
After this first study, the scope extension was achieved using a selection of hydroxy-
pyridines, -pyrazoles, -pyrazine, -pyridazine and -quinoline (11a-o, Table 2). The 
difluoromethylation reaction of these substrates using difluoromethyl triflate was achieved 
with moderate to good yields. Interestingly, all heterocycles used to illustrate this study were 
successfully difluoromethylated, showing the versatility of this method. The possibility of 
using difluoromethyl-nonaflate (F2HC-ONf) to avoid the formation of aryl triflate side-
products was not investigated in this case (as previously achieved by Hartwig’s group). The 
low yields observed in the cases of light substrates can be explained by the volatility of the 
corresponding products (e.g.: entries 7, 8, 12, Table 2). 
 
Table 1: Optimization of the reaction conditions for the difluoromethylation of 6-
chloropyridin-2-ol using difluoromethyl triflate. 
 
Entry Base Solvent Yield [11a] 
1 KOH DMSO 6% 
2 KOH DMF 8% 
3 KOH iPrOH 34% 
4 KOH acetone 67% 
5 KOH DME 66% 
6 KOH dioxane 76% 
7 KOH THF 83% 
8 KOH MeCN 85% 
9 KOHa MeCN 71% 
10 LiOH MeCN 36% 
11 NaOH MeCN 55% 
Reactions were performed on a 0.5 mmol scale and the yields were determined by 19F NMR spectroscopic 
analysis on the crude product using PhCF3 as internal standard. a: 0.5mL KOH instead of 1.0 mL. 
 
It is important to note that several reports have recently described the preparation of 
difluoromethoxylated heterocycles using different difluorocarbene precursors 
([Cu(phen)2][O2CCF2Cl] or fluoroform). In the majority of cases, the reported yields were 
lower, heating the reaction mixture was required, as well as the use of less environmentally 
friendly organic solvents[23, 24]. 
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Table 2: Difluoromethylation of various N-based heterocycles using difluoromethyl triflate. 
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10 
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The reactions were performed on a 1 mmol scale. 
a: yield measured by 19F NMR spectroscopic analysis on the crude product using PhCF3 as internal standard. 
 
As previously mentioned, the F2HC-O-group possesses similar electronic properties to those 
of F3C-O, but with specific features (H-bonding capacity, different conformational behaviour, 
size). Therefore, we decided to apply this approach to the synthesis of F2HC-O-analogues of 
Imidacloprid and Thiacloprid.  
 
For this purpose, the key intermediate 14 was prepared starting from readily available 6-
hydroxynicotinic acid. First, this starting material was converted into 5-
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using thionyl chloride was performed providing the desired product 14. This product was 
further coupled with 4,5-dihydro-N-nitro-1H-imidazol-2-amine or N-(4,5-dihydro-2-thiazolyl) 
cyanamide, to provide the two desired difluoromethoxy analogues of Imidacloprid and 
Thiacloprid (15 and 16) in 74% and 72 % yield respectively (Scheme 2). 
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Scheme 2. Synthesis of F2HCO-Imidacloprid (15) and Thiacloprid (16). 
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vitro, which are significantly lower than the one measured for Imidacloprid (logP-value = 0.6; 
pI50 = 9.1). Despite the fact that 15 (100 g a.i. ha-1) is 5 times more active in vivo against 
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(by a factor of 625) than Imidacloprid (0.16 g a.i. ha-1). A similar result was obtained for the 
two Thiacloprid analogues (9 and 16). Both 6-difluoromethoxy- (16; logP-value = 1.92) and 
6-trifluoromethoxy-analogues (9; logP-value = 2.08) have the same low pI50-values (4.9 vs 
4.8) in vitro, which are significantly lower than the one measured for Thiacloprid (logP-value 
= 1.6; pI50 = 9.2). Contrary to the case of Imidacloprid and of its derivatives 8 and 15, the 
OCF3-Thiacloprid analogue 9 (100 g a.i. ha-1) is 5 times more active in vivo against M. 
persicae than the OCHF2- one (16; 500 g a.i. ha-1); however —as for 8 and 15 compared to 
Imidacloprid— both derivatives 9 and 16 are much less active (by a factor of 125) than 
Thiacloprid (0.8 g a.i. ha-1) (Table 3). 
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Table 3. Biological evaluation of the F3CO- and F2HCO-analogues of imidacloprid (8, 15) 
and thiacloprid (9, 16). 
	
Compound	 Activity	in	vitro	
(pI50-value)	
Activity	in	vivo	
(Myzus	persicae)	[in	g	a.i.	ha-1]	
Imidacloprid	 9.1	 0.16	
8	 5.2	 500	
9	 4.8	 100	
Thiacloprid	 9.2	 0.8	
15	 5.3	 100	
16	 4.9	 500	
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Figure 2. Binding modes of Imidacloprid and Thiacloprid to Ac-AChBP. a) Overlay of two 
neighbouring monomers generated from PDB entry 3C79. The remaining panels zoom into 
the respective structures, but adopt similar perspectives. b) Overlay of Imidacloprid and its 6-
trifluoromethoxy-analogue (8) with the focus on the [O2N-N=]-pharmacophores. c) Overlay 
of Imidacloprid and its 6-difluoromethoxy-analogue (15) with the focus on 6-F2HC-O- and 6-
Cl-pyridin-3-yl residues. d) Overlay of Thiacloprid and its 6-difluoromethoxy-analogue (16) 
with the focus on the [NC-N=]-pharmacophores. e) Overlay of Thiacloprid and its 6-
trifluoromethoxy-analogue (9) with the focus on 6-F3C-O- and 6-Cl-pyridin-3-yl residues. 
Parts of the cysteine loop covering the active site were undisplayed to allow a complete view 
on the ligand orientations. The	images	shown	above	were	generated	using	the	molecular	
modeling	software	suite		SYBYLx2.2.[26]	
 
 
While it has been difficult to obtain crystals of any nAChR of sufficient quality to conduct 
high-resolution X-ray crystallography, both the crystal structure of a soluble homopentameric 
acetylcholine binding protein isolated from the seawater mollusc Aplysia californica (Ac-
AChBP) and the only recently added crystal structure of the human a4b2 acetylcholine 
receptor[27] can be used to provide considerable support to the understanding of ligand–
receptor interactions[28]. Figure 2 compares the mode of binding of Imidacloprid and its 6-
difluoromethoxy-analogue (15) as well as Thiacloprid and its 6-trifluoromethoxy-analogue 
(9) to Ac-AChBP from A. californica. The Figure 2 has been created from PDB entry 3C79 
(Imidacloprid in complex with Ac-AChBP)[29] following the procedure described by Beck et 
al.[30]. In both cases, the positively polarized N-nitroguanidine and N-cyano-amidine π-
systems of Imidacloprid and 15 as well as Thiacloprid and 9 demonstrate a perfect overlay as 
shown in Figures 2b and 2d.  
 
In addition, a strikingly conserved water molecule mediates a hydrogen bridge between the 
pyridine nitrogen atoms of all neonicotinoids and the loop D backbone, which is known to be 
important for ligand binding. However, the overlay of Imidacloprid and 15 with the focus on 
6-F2HC-O- and 6-Cl-pyridin-3-yl residues (Figure 2c) as well as Thiacloprid and 9 with the 
focus on 6-F3C-O- and 6-Cl-pyridin-3-yl residues (Figure 2e) clearly demonstrates the 
differences between the two commercial neonicotinoids and their fluoroalkoxy-containing 
analogues. Both the F2HCO- and F3CO-groups in 6-position of the pyridine are much larger 
(see dotted circles in Figure 2c and 2e) compared to a chlorine atom and therefore disruptive 
for the ligand-receptor interaction. In addition, the groups tend to adopt perpendicular position 
as described for (hetero)aromatic ring systems[31, 32]. As a consequence of these structural 
modifications the insecticidal activity of 15 and 9 decreased remarkably. 
 
3. Conclusion 
 
To illustrate the potential of the F3CO- and F2HCO-groups as emergent fluorinated 
substituents (EFS), analogues of Imidacloprid and Thiacloprid displaying a replacement of the 
key chlorine atom by these two groups have been prepared and evaluated. For the preparation 
of the key intermediates, we have developed an efficient synthetic route to prepare the desired 
F3CO-intermediate; in a second hand, we have developed a novel strategy to prepare F2HCO-
substituted heterocycles, and this strategy was applied to the preparation of the desired 
F2HCO-intermediate. With both key intermediates, F3CO- and F2HCO-analogues of 
Imidacloprid and Thiacloprid were prepared. While the in-vitro activity of these analogues is 
promising, their in-vivo activity revealed to be much less elevated. However, this 
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investigation opens the route to a new access to analogues of bioactive ingredients and their 
further evaluation, which could possibly lead to large activity enhancements. 
 
 
4. Experimental 
 
 General 
All reactions were performed in flame-dried glassware using sealed tube or Schlenk tube. 
Liquids and solutions were transferred with syringes. Air- and moisture- sensitive materials 
were stored protected and handled under an atmosphere of argon, with appropriate glassware. 
Solvents were purified and dried following standard procedures: tetrahydrofuran (THF) was 
distilled from sodium or sodium + benzophenone prior to use. Anhydrous MeCN was used 
from commercial source and was stored under Argon. Technical grade solvents for extraction 
and chromatography (cyclohexane, dichloromethane, n-pentane, ether, toluene, and ethyl 
acetate) were used without purification. All reagents were purchased from standard suppliers 
(Sigma Aldrich, ABCR, Alfa Aesar and Apollo scientific). Starting materials, if commercial, 
were purchased and used as such, provided that adequate checks (NMR) had confirmed the 
claimed purity. Analytical thin-layer chromatography (TLC) was performed on silica gel. 
Flash column chromatography was performed on silica gel 60 (40–63 μm, 230–400 mesh, 
ASTM) by Merck using the indicated solvents. 1H, 13C, and 19F-NMR spectra were recorded 
in CDCl3 on Bruker AV 400 instruments (1H: 400MHz, 19F: 376MHz, 13C: 100MHz, 11B: 
128MHz). Chemical shifts are reported in parts per million (ppm) downfield from 
tetramethylsilane and are referenced to the residual solvent resonance as the internal standard 
(chloroform (δ  [1H] 7.26 and accordingly δ [13C] 77.16 ppm), CD3CN (δ [1H] 1.94 and 
accordingly δ [13C] 1.32 ppm, MeOD-d4 (δ [1H] 3.31 and accordingly δ [13C] 49.00 ppm), 
DMSO-d6 (δ [1H] 2.50 and accordingly δ [13C] 39.52 ppm) or Acetone-d6 (δ [1H] 2.05 and 
accordingly δ [13C] 29.84 ppm). Data are reported as follows: chemical shift, multiplicity (br s 
= broad singlet, s = singlet, d = doublet, t = triplet, q = quartet, quint = quintet, m = multiplet, 
br d = broad doublet), coupling constant (Hz) and integration. Fluorobenzene (d [19F] -113.15 
ppm) was used as internal standard to measure yields in-situ. The spectra were processed with 
the program NMR Notebook (Version 2.70, NMRtec). Experiments under microwave 
irradiation were carried out on an InitiatorTM apparatus from Biotage, exact parameters are 
given with the procedures. Melting points (M.p.) were determined for crystalline or solid 
compounds with a Melting Point Apparatus M-560 and are not corrected. High resolution 
mass spectrometry (HRMS) analysis and elemental analysis (Anal.) were performed by the 
analytical facility at the University of Strasbourg (measurement accuracy ≤ 15 ppm). Spectral 
data were recorded from samples purified by Hickmann distillation when necessary. 
 
 F3CO-Imidacloprid and F3CO-Thiacloprid 
 
 2-Chloro-6-trichloromethoxypyridine (1) 
Thiophosgene (3.0 mL, 39 mmol, 1 equiv.) in dichloromethane (24 mL) was added dropwise 
to a solution of 2-chloro-6-hydroxypyridine (5.0 g, 39 mmol) in aqueous sodium hydroxide 
(5%, 34 mL) at 0 °C. The reaction mixture was vigorously stirred for 2 h at 0 °C before being 
extracted with dichloromethane (3 x 20 mL). The combined organic layers were washed with 
1M HCl (20 mL) and water (20 mL) and dried with sodium sulphate before being evaporated. 
The crude product was taken up in chloroform (40 mL) and the reaction mixture was then 
saturated with chlorine at 25 °C until the reaction mixture began to warm up. After 2 h at 25 
°C, excess chlorine was again added until a yellow solution was obtained. After 24 h at 25 °C, 
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excess chlorine was removed with a stream of argon and the solution was concentrated. The 
crude pale-yellow oil was distilled under reduced pressure to afford pure 2-chloro-6-
trichloromethoxypyridine (1). Colourless oil (5.7 g, 60% yield), b.p. = 80–82 °C (1 mbar); 1H 
NMR (CDCl3, 300 MHz, 25 °C): δ 7.70 (t, 1 H, J = 7.9 Hz, H-4), 7.19 (d, 1 H, J = 7.9 Hz, H-
5), 7.02 (d, J = 7.9 Hz, 1 H, H-3) ppm; 13C NMR (CDCl3, 75 MHz, 25 °C): δ 151.8 (C), 149.0 
(C), 141.7 (CHarom), 122.2 (CHarom), 112.7 (CHarom), 109.1 (OCCl3). Spectroscopic data 
were in agreement with literature values[17]. 
 
 2-Chloro-6-trifluoromethoxypyridine (2) 
2-Chloro-6-trichloromethoxypyridine (1, 5.9 g, 24 mmol, 1 equiv.) was added dropwise at 
120 °C to a mixture of SbF3 (8.7 g, 48 mmol, 2 equiv.) and SbCl5 (0.60 mL, 4.8 mmol, 0.2 
equiv.) and the mixture was stirred for 3 h at 140 °C. GC monitoring indicated 100% 
conversion and disappearance of the -OCF2Cl byproduct. The mixture was then cooled to 
room temperature and dissolved in dichloromethane (100 mL). The solution was washed with 
2M HCl (150 mL) and the aqueous layer was extracted with dichloromethane (2 x 50 mL). 
The combined organic layers were dried over sodium sulphate and the solvent was evaporated 
at atmospheric pressure. The crude product was distilled under reduced pressure to afford 
pure 2-chloro-6-trifluoromethoxypyridine (2). Colourless oil (2.5 g, 53% yield), b.p. = 42–44 
°C (20 mbar); 1H NMR (CDCl3, 300 MHz, 25 °C): δ 7.67 (t, 1 H, J = 7.9 Hz, H-4), 7.18 (d, 1 
H, J = 7.9 Hz, H-5), 6.87 (d, 1 H, J = 7.9 Hz, H-3) ppm; 13C NMR (CDCl3, 75 MHz, 25 °C): δ 
155.6 (C), 149.3 (C), 142.0 (CHarom), 122.2 (CHarom), 119.8 (q, JC-F = 262.1 Hz, OCF3), 
111.1 (CH); 19F NMR (CDCl3, 282 MHz, 25 °C): δ -57.2 ppm. Spectroscopic data were in 
agreement with literature values[17]. 
 
 2-Chloro-6-(trifluoromethoxy)-5-(trimethylsilyl)pyridine (3) 
Butyllithium (1.56 M in hexanes, 5.7 mL, 8.9 mmol, 1.1 equiv.) was added dropwise at 0 °C 
to a solution of diisopropylamine (1.2 mL, 8.9 mmol, 1.1 equiv.) in THF (15 mL). A solution 
of 2-chloro-6-(trifluoromethoxy)pyridine 2 (1.6 g, 8.1 mmol, 1 equiv.) in THF (5 mL) was 
added dropwise at -78 °C, and the reaction mixture was stirred for 2 h at this temperature. 
Chlorotrimethylsilane (1.0 g, 1.13 mL, 8.9 mmol, 1.1 equiv.) was then added dropwise and 
the mixture was allowed to reach 25 °C before being neutralised with water (20 mL) and 
extracted with diethyl ether (3 x 10 mL). The combined organic layers were dried over 
sodium sulphate and concentrated in vacuo. The crude product was distilled under reduced 
pressure to afford pure 2-chloro-6-(trifluoromethoxy)-5-(trimethylsilyl)pyridine (3). 
Colourless oil (1.5 g, 68%), b.p. = 89–93 °C (14 mbar); 1H NMR (CDCl3, 300 MHz, 25 °C): δ 
7.78 (d, 1 H, J = 7.6 Hz, H-3), 7.22 (d, 1 H, J = 7.6 Hz, H-4), 0.34 (s, 9 H, SiMe3) ppm. 
Spectroscopic data were in agreement with literature values[17]. 
 
 2-Chloro-6-trifluoromethoxynicotinic acid (4) 
Butyllithium (1.56 M in hexanes, 3.7 mL, 5.7 mmol, 1.1 equiv.) was added dropwise at 0 °C 
to a solution of 2,2,6,6-tetramethylpiperidine (1.0 mL, 5.7 mmol, 1.1 equiv.) in THF (10 mL). 
A solution of 2-chloro-6-(trifluoromethoxy)-5-(trimethylsilyl)pyridine 3 (1.4 g, 5.2 mmol, 1 
equiv.) in THF (5 mL) was added dropwise at -78 °C, and the reaction mixture was stirred for 
2 h at this temperature. The mixture was then poured onto an excess of freshly crushed dry ice 
before being treated with an aqueous solution of sodium hydroxide (5%, 10 mL). The 
resulting aqueous layer was collected, washed with diethyl ether (10 mL), and acidified to pH 
= 1 by dropwise addition of 6M HCl (4 mL). After extraction with ethyl acetate (3 x 10 mL), 
the combined organic layers were dried over sodium sulphate and evaporated. The crude oil 
was treated with tetrabutylammonium fluoride (1M in THF, 5.7 mL, 5.7 mmol, 1.1 equiv.) for 
20 h at 25 °C. The mixture was then neutralised by addition of 2M HCl (10 mL) and extracted 
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with ethyl acetate (3 x 10 mL). The combined organic layers were dried over sodium sulphate 
and evaporated to afford pure 2-chloro-6-(trifluoromethoxy)nicotinic acid (4). Colourless 
powder (0.92 g, 70%); 1H NMR (CD3OD, 300 MHz, 25 °C): δ 8.44 (d, 1H, J = 8.3 Hz, H-4), 
7.21 (d, 1 H, J = 8.3 Hz, H-5) ppm. Spectroscopic data were in agreement with literature 
values[17]. 
 
 6-Trifluoromethoxynicotinic acid (5) 
Palladium (10% on charcoal, 2.1 g, 2.0 mmol, 10 mol%) was added at 25 °C with stirring to a 
solution of 2-chloro-6-trifluoromethoxynicotinic acid 4 (4.8 g, 20 mmol, 1 equiv.) and 
ammonium formate (2.5 g, 40 mmol, 2 equiv.) in methanol (40 mL). The reaction mixture 
was stirred for 16 h at room temperature before being filtered on Celite®, the filtrate was 
concentrated and the residue was taken up in ethyl acetate (50 mL). The organic layer was 
washed with 2M HCl (2 x 20 mL) and water (20 mL). The organic layer was dried over 
sodium sulphate and evaporated in vacuo to afford pure 6-(trifluoromethoxy)nicotinic acid 
(5). Colourless powder (3.2 g, 76%); 1H NMR (CD3OD, 300 MHz, 25 °C): δ 8.91 (d, 1 H, Jm 
= 2.3 Hz, H-2), 8.48 (dd, 1 H, Jo = 8.4, Jm = 2.3 Hz, H-4), 7.24 (d, 1 H, Jo = 8.4 Hz, H-5) 
ppm. Spectroscopic data were in agreement with literature values[17]. 
 
 (6-(Trifluoromethoxy)pyridin-3-yl)methanol (6) 
BH3.THF (1M in THF, 36 mL, 36 mmol, 5 equiv.) was added dropwise to 6-trifluoromethoxy 
nicotinic acid 5 (1.5 g, 7.3 mmol, 1 equiv.) in solution in THF (25 mL) at 0 °C. The reaction 
mixture was stirred 30 min at this temperature, and allowed to reach room temperature 
overnight. It was quenched with methanol (25 mL), diluted with diethyl ether (100 mL) and 
the organic layer was washed with brine (2 x 100 mL). The combined organic layers were 
dried with sodium sulphate and the solvent was distilled off. The crude product was purified 
by column chromatography on silica gel with pentane/diethyl ether (6:4 to 3:7) as eluent, 
which afforded 6. Colourless oil (1.0 g, 70%); 1H NMR (CDCl3, 300 MHz, 25 °C): δ 8.28 (d, 
J = 2.4 Hz, 1 H, H-2), 7.82 (dd, 1 H, Jo = 8.4 Hz, Jm = 2.4 Hz, H-4), 7.03 (d, 1 H, J = 8.4 Hz, 
H-5), 4.73 (s, 2H, CH2), 2.36 (brs, 1H, -OH) ppm.; 13C NMR (CDCl3, 75 MHz, 25 °C): δ 
156.5 (C-6), 146.7 (C-2), 139.7 (C-4), 135.6 (C-3), 120.6 (q, JC-F = 259.2 Hz, OCF3), 62.1 
(CH2) ppm; 19F NMR (CDCl3, 282 MHz, 25 °C): δ -56.7 ppm; HRMS (ESI Positive) for 
C7H7F3NO2 [M+H]: calcd. 194.043; found 194.044. 
 
 3-(Chloromethyl)-6-(trifluoromethoxy) pyridine (7) 
Mesyl chloride (0.28 mL, 3.6 mmol, 1.5 equiv.) was added dropwise to a solution of (6-
(trifluoromethoxy)pyridin-3-yl)methanol 6 (0.50 g, 2.4 mmol, 1 equiv.) in dichloromethane (8 
mL) in presence of triethylamine (0.60 g, 0.79 mL, 5.7 mmol, 2.4 equiv.) at 0 °C. The 
reaction mixture was allowed to reach room temperature overnight. It was then poured into a 
saturated solution of sodium hydrogen carbonate (10 mL). The aqueous layer was extracted 
with dichloromethane (3 x 15 mL) and washed with water (2 x 10 mL). The combined 
organic layers were dried over sodium sulphate and the solvent was distilled off. The crude 
product was purified by column chromatography on silica gel with pentane/diethyl ether (9:1) 
as eluent, which afforded 7. Pale yellow oil (0.31 g, 56%);1H NMR (CDCl3, 300 MHz, 25 
°C): δ 8.32 (d, 1 H, J = 2.4 Hz, H-2), 7.85 (dd, 1 H, Jm = 2.4 Hz, Jo = 8.4 Hz, H-4), 7.03 (d, 1 
H, J = 8.4 Hz, H-5), 4.59 (s, 2H, CH2) ppm; 13C NMR (CDCl3, 75 MHz, 25 °C): δ 156.5 (C-
6), 147.4 (C-2), 140.6 (C-4), 131.6 (C-3), 120.0 (q, OCF3, JC-F = 260.1 Hz), 42.0 (CH2) ppm; 
19F NMR (CDCl3, 282 MHz, 25 °C): δ -56.6 ppm; MS (EI): m/z = 211.1 [M+], 176.0 [M+-Cl]. 
 
  N-(1-((6-(Trifluoromethoxy)pyridin-3-yl)methyl)-4,5-dihydro-1H-imidazol-2-
yl)nitramide (8) 
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3-(Chloromethyl)-6-(trifluoromethoxy)pyridine 7 (0,15 g, 0.69 mmol, 0.90 equiv.) was added 
dropwise to a solution of 4,5-dihydro-N-nitro-1H-imidazol-2-amine (0,10 g, 0.76 mmol, 1 
equiv.), potassium carbonate (0.10 g, 0.73 mmol, 0.96 equiv.) and caesium chloride (5.0 mg, 
0.030 mmol, 0.03 equiv.) in acetonitrile (5 mL) at room temperature. The reaction mixture 
was stirred 5 hours at room temperature. It was then filtrated and the solvent was distilled off. 
The crude product was purified by HPLC on reverse phase with water/acetonitrile gradient, 
which afforded 8 (89.0 mg, 38% yield); 1H NMR (DMSO-d6, 150 MHz): δ 3.50 (m, 2H, 
CH2), 3.63 (m, 2H, CH2), 4.50 (s, 2H, CH2), 7.31 (d, 2H, C-H, Py, J = 8.4 Hz), 7.96 (dd, 1H, 
C-H, Py, J = 8.4 Hz, J = 2.5 Hz), 8.32 (d, 1H, C-H, Py, J = 2.5 Hz), 9.00 (s, 1H, NH); 13C 
NMR (proton-decoupled) (DMSO-d6, 150 MHz): δ 41.8, 44.6, 45.3 (CH2), 113.4 (C-H, Ph), 
119.9 (OCF3), 131.5 (C, Ph), 141.3, 147.3 (C-H, Ph), 155.5 (C-O, Ph), 160.5 (C=N) ppm; 19F 
NMR (DMSO-d6, 566 MHz): δ = -54.7 ppm. HRMS (ESI) calcd for C10H11F3N5O3 [M+H]+: 
306.0814. Found: 306.0816. 
	
 N-(3-((6-(Trifluoromethoxy)pyridin-3-yl)methyl)thiazolidin-2-
ylidene)cyanamide (9) 
3-(Chloromethyl)-6-(trifluoromethoxy)pyridine 7 (0.15 g, 0.69 mmol, 0.90 equiv.) was added 
dropwise to a solution of N-(4,5-dihydro-2-thiazolyl)cyanamide (98 mg, 0.76 mmol, 1 
equiv.), potassium carbonate (0.10 g, 0.73 mmol, 0.96 equiv.) and caesium chloride (5.0 mg, 
0.030 mmol, 0.03 equiv.) in acetonitrile (5 mL) at room temperature. The reaction mixture 
was stirred 5 hours at room temperature. It was then filtrated and the solvent was distilled off. 
The crude product was purified by HPLC on reverse phase with water/acetonitrile gradient, 
which afforded 9 (172.6 mg, 74% yield); 1H NMR (CD3CN, 150 MHz): δ 3.41 (m, 2H, CH2), 
3.85 (m, 2H, CH2), 4.61 (s, 2H, CH2), 7.12 (d, 2H, C-H, Py, J = 8.4 Hz), 7.87 (dd, 1H, C-H, 
Py, J = 8.4 Hz, J = 2.5 Hz), 8.23 (d, 1H, C-H, Py, J = 2.5 Hz); 13C NMR (proton-decoupled) 
(CD3CN, 150 MHz): δ 28.3, 47.4, 53.6 (CH2), 114.1 (C-H, Py), 121.1 (OCF3), 131.0 (C, Py), 
142.0, 148.4 (C-H, Py), 157.1 (C-O, Py), 176.3 (C=N); 19F NMR (CDCN, 566 MHz): δ = -
55.8 ppm. HRMS (ESI) calcd for C10H10F3N4OS [M+H]+: 303.0527. Found: 303.0526.  
 
 F2HCO-Imidacloprid and F2HCO-Thiacloprid 
 
 Preparation of 2-chloro-6-(difluoromethoxy)pyridine (11a). General 
procedure for the difluoromethylation of hydroxyl-substituted heteroaromatics 
To a vigorously stirred solution of 2-chloro-6-hydroxypyridine (0.13 g, 1.0 mmol) in 
acetonitrile (2 mL) at room temperature was added a 6M aqueous solution of potassium 
hydroxide (2 mL). Difluoromethyltriflate (0.38 mL, 3.0 mmol, 3 equiv.) was added dropwise 
to the reaction mixture which was maintained at room temperature by means of a water bath 
(the reaction is exothermic), and the medium was stirred for 30 min. The mixture was diluted 
with water (20 mL) and extracted with diethyl ether (2 x 10 mL) and ethyl acetate (3 x 10 
mL). The combined organic layers were dried over Na2SO4, filtered and evaporated under 
reduced pressure. The crude material was purified by column chromatography on silica gel 
with pentane/diethyl ether (100:0 to 70:30) as eluent to afford the pure title compound (129 
mg, 72% yield); 1H-NMR (400 MHz, CDCl3): δ 7.62 (t, 1H, J = 7.9 Hz), 7.37 (t, 1H, J = 
72.2 Hz), 7.07 (d, 1H, J = 7.9 Hz), 6.76 (d, 1H, J = 8.0 Hz) ppm. 13C-NMR (101 MHz, 
CDCl3): δ 158.3, 148.5, 142.1, 120.1, 113.8 (t, J = 259 Hz), 109.6 ppm. 19F-NMR (376 
MHz, CDCl3): δ -89.3 (d, 2F, J = 71.4 Hz) ppm. HRMS (ESI) calcd for C6H5ClF2NO 
[M+H]+: 180.002. Found: 180.000. Spectroscopic data were in agreement with literature 
values[17]. 
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 2-Chloro-5-(difluoromethoxy)pyridine (11b).  
The crude material was purified by column chromatography on silica gel with pentane/diethyl 
ether (100:0 to 70:30) as eluent to afford the pure title compound (133 mg, 74%). 1H-NMR 
(400 MHz, CDCl3): δ 8.16 (d, 1H, J = 2.8 Hz), 7.37 (dd, 1H, J = 8.8 Hz, J = 2.8 Hz), 7.24 (d, 
1H, J = 8.8 Hz), 6.44 (t, 1H, J = 72.2 Hz) ppm. 13C-NMR (101 MHz, CDCl3): δ 147.8, 
146.2, 141.9, 130.8, 124.9, 115.1 (t, J = 266 Hz) ppm. 19F-NMR (376 MHz, CDCl3): δ -81.9 
(d, 2F, J = 72.5 Hz) ppm. HRMS (ESI) calcd for C6H5ClF2NO [M+H]+: 180.002. Found: 
180.004. Spectroscopic data were in agreement with literature values[17]. 
 
 2-Chloro-4-(difluoromethoxy)pyridine (11c). 
The crude material was purified by column chromatography on silica gel with pentane/diethyl 
ether (100:0 to 70:30) as eluent to afford the pure title compound (74 mg, 41%). 1H-NMR 
(400 MHz, CDCl3): δ 8.36 (d, 1H, J = 5.6 Hz), 7.08 (s, 1H), 6.99 (m, 1H), 6.65 (t, 1H, J = 
71.6 Hz) ppm. 13C-NMR (101 MHz, CDCl3): δ 158.9, 152.9, 151.1, 114.6 (t, JC-F = 265.2 
Hz), 113.7, 112.4 ppm. 19F-NMR (376 MHz, CDCl3): δ -83.6 (d, 2F, J = 72.6 Hz) ppm. 
HRMS (ESI) calcd for C6H5ClF2NO [M+H]+: 180.0022. Found: 180.0038. 
 
 2-Bromo-3-(difluoromethoxy)pyridine (11d).  
The crude material was purified by column chromatography on silica gel with pentane/diethyl 
ether (100:0 to 70:30) as eluent to afford the pure title compound (170 mg, 76%). 1H-NMR 
(400 MHz, CDCl3): δ 8.28 (d, 1H, J = 4.6 Hz), 7.56 (d, 1H, J = 8.4 Hz), 7.31 (m, 1H), 6.60 
(t, 1H, J = 73.0 Hz) ppm. 13C-NMR (101 MHz, CDCl3): δ 146.7, 145.1, 135.9, 129.3, 123.5, 
115.3 (t, JC-F = 264.5 Hz) ppm. 19F-NMR (376 MHz, CDCl3): δ -82.0 (d, 2F, J = 72.6 Hz) 
ppm. HRMS (ESI) calcd for C6H5BrF2NO [M+H]+: 223.952. Found: 223.952. Spectroscopic 
data were in agreement with literature values[17]. 
 
 3-Bromo-2-(difluoromethoxy)pyridine (11e).  
The crude material was purified by column chromatography on silica gel with pentane/diethyl 
ether (100:0 to 70:30) as eluent to afford the pure title compound (101 mg, 45%). 1H-NMR 
(400 MHz, CDCl3): δ 8.13 (d, 1H, J = 4.6 Hz), 7.94 (d, 1H, J = 7.7 Hz), 7.46 (t, 1H, J = 72.4 
Hz), 7.01 (dd, 1H, J = 7.5 Hz, J = 4.8 Hz) ppm. 13C-NMR (101 MHz, CDCl3): δ 155.5, 
145.5, 143.2, 121.1, 114.2 (t, JC-F = 257.2 Hz), 106.8 ppm. 19F-NMR (376 MHz, CDCl3): δ -
89.3 (d, 2F, J = 72.1 Hz) ppm. HRMS (ESI) calcd for C6H5BrF2NO [M+H]+: 223.952. Found: 
223.952. 
 
 2,4-Dichloro-5-(difluoromethoxy)pyridine (11f).  
The crude material was purified by column chromatography on silica gel with pentane/diethyl 
ether (100:0 to 70:30) as eluent to afford the pure title compound (141 mg, 66%). 1H-NMR 
(400 MHz, CDCl3): δ 8.32 (s, 1H), 7.47 (s, 1H), 6.60 (t, 1H, J = 72.1 Hz) ppm. 13C-NMR 
(101 MHz, CDCl3): δ 148.5, 143.1, 138.8, 125.7, 115.0 (t, JC-F = 267.1 Hz), 110.2 ppm. 19F-
NMR (376 MHz, CDCl3): δ -81.8 (d, 2F, J = 72.0 Hz) ppm. HRMS (ESI) calcd for 
C6H4Cl2F2NO [M+H]+: 213.964. Found: 213.963. 
 
 5-(Difluoromethoxy)-2-methylpyridine (11g). 
The crude material was purified by column chromatography on silica gel with pentane/diethyl 
ether (100:0 to 70:30) as eluent to afford the pure title compound (49 mg, 31%). 1H-NMR 
(400 MHz, CDCl3): δ 8.20 (s, 1H), 7.23 (m, 1H), 7.00 (d, 1H, J = 8.8 Hz), 6.35 (t, 1H, J = 
73.0 Hz), 2.40 (s, 3H) ppm. 13C-NMR (101 MHz, CDCl3): δ 154.5, 143.9, 140.1, 126.8, 
	 17	
122.3, 114.1 (t, JC-F = 262.1 Hz), 22.4 ppm. 19F-NMR (376 MHz, CDCl3): δ -81.2 (d, 2F, J 
= 74.8 Hz) ppm. HRMS (ESI) calcd for C7H8F2NO [M+H]+: 160.057. Found: 160.058. 
 
 3-(Difluoromethoxy)pyridine (11h).  
The crude material was purified by column chromatography on silica gel with pentane/diethyl 
ether (100:0 to 70:30) as eluent to afford the pure title compound (46 mg, 32%). 
Spectroscopic data were in agreement with literature values[17]. 
 
 Ethyl 2-(difluoromethoxy)nicotinate (11i).  
The crude material was purified by column chromatography on silica gel with pentane/diethyl 
ether (100:0 to 60:40) as eluent to afford the pure title compound (61 mg, 28%). 1H-NMR 
(400 MHz, CDCl3): δ 8.32 (dd, 1H, J = 4.8 Hz, J = 2.0 Hz), 8.27 (dd, 1H, J = 7.7 Hz, J = 2.0 
Hz), 7.53 (t, 1H, J = 72.4 Hz), 7.19 (dd, 1H, J = 7.6 Hz, J = 4.8 Hz), 4.41 (q, 2H, J = 7.3 Hz), 
1.41 (t, 3H, J = 7.2 Hz) ppm. 13C-NMR (101 MHz, CDCl3): δ 163.9, 157.1, 150.2, 142.1, 
119.7, 115.4, 114.0 (t, JC-F = 251.8 Hz), 61.8, 14.1 ppm. 19F-NMR (376 MHz, CDCl3): δ -
89.3 (d, 2F, J = 71.7 Hz) ppm. HRMS (ESI) calcd for C9H9F2NNaO3 [M+Na]+: 240.0443. 
Found: 240.0414. 
 
 5-(Difluoromethoxy)-3-(difluoromethyl)-1-methyl-1H-pyrazole (11j).  
The crude material was purified by column chromatography on silica gel with pentane/diethyl 
ether (100:0 to 60:40) as eluent to afford the pure title compound (149 mg, 75%). 1H-NMR 
(400 MHz, CDCl3): δ 6.48 (t, 1H, J = 55.0 Hz), 6.47 (t, 1H, J = 71.9 Hz), 6.04 (s, 1H), 3.69 
(s, 3H) ppm. 13C-NMR (101 MHz, CDCl3): δ 145.3, 145.1 (t, JC-F = 29.8 Hz), 114.9 (t, JC-F 
= 268.2 Hz), 111.0 (t, JC-F = 235.6 Hz), 89.4, 34.8 ppm. 19F-NMR (376 MHz, CDCl3): δ -
83.9 (d, 2F, J = 71.8 Hz), -112.3 (d, 2F, J = 55.0 Hz) ppm. HRMS (ESI) calcd for C6H7F4N2O 
[M+H]+: 199.049. Found: 199.050. 
 
 Ethyl 3-bromo-5-(difluoromethoxy)-1-methyl-1H-pyrazole-4-carboxylate 
(11k). 
The crude material was purified by column chromatography on silica gel with pentane/diethyl 
ether (100:0 to 60:40) as eluent to afford the pure title compound (120 mg, 40%). 1H-NMR 
(400 MHz, CDCl3): δ 6.98 (t, 1H, J = 74.0 Hz), 4.34 (q, 2H, J = 7.5 Hz), 3.78 (s, 3H), 1.38 
(t, 3H, J = 7.5 Hz) ppm. 13C-NMR (101 MHz, CDCl3): δ 160.5, 146.8 (t), 126.9, 116.7 (t), 
101.9, 61.1, 35.3, 14.1 ppm. 19F-NMR (376 MHz, CDCl3): δ -83.3 (d, 2F, J = 74.7 Hz) ppm. 
HRMS (ESI) calcd for C8H9BrF2N2NaO3 [M+Na]+: 320.966. Found: 320.965. 
 
 5-(Difluoromethoxy)-1,3-dimethyl-1H-pyrazole (11l).  
The crude material was purified by column chromatography on silica gel with pentane/diethyl 
ether (100:0 to 60:40) as eluent to afford the pure title compound (57 mg, 35%). 1H-NMR 
(400 MHz, CDCl3): δ 6.47 (t, 1H, J = 72.5 Hz), 5.65 (s, 1H), 3.66 (s, 3H), 2.21 (s, 3H) ppm. 
13C-NMR (101 MHz, CDCl3): δ 147.3, 145.2, 115.1 (t, JC-F = 264.2 Hz), 90.8, 34.0, 14.3 
ppm. 19F-NMR (376 MHz, CDCl3): δ -83.6 (d, 2F, J = 72.3 Hz) ppm. HRMS (ESI) calcd for 
C6H9F2N2O [M+H]+: 163.0677. Found: 163.0674. 
 
 3-Chloro-6-(difluoromethoxy)pyridazine (11m).  
The crude material was purified by column chromatography on silica gel with pentane/diethyl 
ether (100:0 to 60:40) as eluent to afford the pure title compound (107 mg, 59%). 1H-NMR 
(400 MHz, CDCl3): δ 7.52 (t, 1H, J = 71.1 Hz), 7.48 (d, 1H, J = 9.0 Hz), 7.06 (d, 1H, J = 9.0 
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Hz) ppm. 13C-NMR (101 MHz, CDCl3): δ 160.9, 153.9, 132.4, 119.9, 113.4 (t, JC-F = 259.2 
Hz) ppm. 19F-NMR (376 MHz, CDCl3): δ -88.9 (d, 2F, J = 71.0 Hz) ppm. HRMS (ESI) calcd 
for C5H4ClF2N2O [M+H]+: 180.997. Found: 180.997. 
 
 2-Bromo-5-(difluoromethoxy)pyrazine (11n).  
The crude material was purified by column chromatography on silica gel with pentane/diethyl 
ether (100:0 to 60:40) as eluent to afford the pure title compound (119 mg, 53%). 1H-NMR 
(400 MHz, CDCl3): δ 8.19 (d, 1H, J = 1.2 Hz), 8.10 (d, 1H, J = 1.2 Hz), 7.25 (t, 1H, J = 71.8 
Hz) ppm. 13C-NMR (101 MHz, CDCl3): δ 155.0, 143.4, 135.2, 134.5, 113.8 (t) ppm. 19F-
NMR (376 MHz, CDCl3): δ -89.1 (d, 2F, J = 72.0 Hz) ppm. HRMS (ESI) calcd for 
C5H4BrF2N2O [M+H]+: 224.9470. Found : 224.9473. 
 
 4-(Difluoromethoxy)quinoline (11o).  
The crude material was purified by column chromatography on silica gel with pentane/diethyl 
ether (100:0 to 60:40) as eluent to afford the pure title compound (61 mg, 31%). 1H-NMR 
(400 MHz, CDCl3): δ 8.73 (d, 1H, J = 4.8 Hz), 8.10 (d, 1H, J = 8.4 Hz), 8.02 (d, 1H, J = 8.4 
Hz), 7.68 (t, 1H, J = 7.2 Hz), 7.50 (t, 1H, J = 7.8 Hz), 6.93 (s, 1H), 6.75 (t, 1H, J = 72.2 Hz) 
ppm. 13C-NMR (101 MHz, CDCl3): δ 154.4, 150.7, 149.8, 130.5, 129.2, 127.0, 121.5, 120.8, 
115.3 (t, JC-F = 261.1 Hz), 105.8 ppm. 19F-NMR (376 MHz, CDCl3): δ -82.9 (d, 2F, J = 72.6 
Hz) ppm. HRMS (ESI) calcd for C10H8F2NO [M+H]+: 196.057. Found: 196.058. 
 
 5-(Hydroxymethyl)pyridin-2-ol or 5-(hydroxymethyl)pyridin-2(1H)-one (12).  
To a stirred solution of 6-hydroxynicotinic acid (10 g, 72 mmol) in absolute ethanol (500 mL) 
was added sulfuric acid (4 mL) at room temperature. The mixture was heated to reflux for 48 
h. After cooling down to room temperature, water (50 mL) was added and the reaction 
mixture was neutralized to pH = 6-7 by portionwise addition of sodium hydrogen carbonate 
(caution: gas evolution). The mixture was evaporated under reduced pressure (most of ethanol 
was removed), and the residue was extracted with ethyl acetate (3 x 50 mL). The combined 
organic extracts were washed with brine, dried over Na2SO4 and evaporated under reduced 
pressure leading to the pure ethyl 6-hydroxynicotinate[30] (10 g, 86%). 1H-NMR (400 MHz, 
CDCl3): δ 13.07 (s, 1H), 8.14 (s, 1H), 7.94 (d, 1H, J = 9.9 Hz), 6.51 (d, 1H, J = 9.4 Hz), 4.25 
(q, 2H, J = 7.1 Hz), 1.29 ppm.  
 
To a stirred solution of lithium aluminium hydride (1.4 g, 37 mmol, 1.2 equiv.) in anhydrous 
THF (20 mL) at room temperature was added dropwise over 1 h a solution of ethyl 6-
hydroxynicotinate (5.1 g, 31 mmol) in anhydrous THF (150 mL) at the same temperature. The 
mixture was stirred at room temperature for 2 h and then heated to reflux for 30 min. The 
reaction mixture was cooled down to 0 °C and quenched with ethyl acetate (12 mL) and water 
(6 mL). The solvents were removed and the residue was taken up in refluxing ethanol (200 
mL). The solution was filtered through Celite® and ethanol was evaporated under reduced 
pressure. The crude material was purified by column chromatography on silica gel with ethyl 
acetate/methanol (75:25) as eluent to afford the pure title compound 12 (2.3 g, 60%). 1H-
NMR (400 MHz, DMSO-d6): δ 11.56 (s, 1H), 7.43 (dd, 1H, J = 9.1 Hz, J = 2.5 Hz), 7.25 (d, 
1H, J = 2.5 Hz), 6.30 (d, 1H, J = 9.1 Hz), 5.22 (t, 1H, J = 5.6 Hz), 4.20 (d, 2H, J = 5.6 Hz) 
ppm. 13C-NMR (101 MHz, DMSO-d6): δ 162.6, 142.0, 133.0, 120.1, 119.6, 60.1 ppm. 
HRMS (ESI) calcd for C6H8NO2 [M+H]+: 126.056. Found: 126.055. 
 
 5-(((tert-Butyldimethylsilyl)oxy)methyl)-2-(difluoromethoxy)pyridine (13).  
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To a stirred solution of 5-(hydroxymethyl)pyridin-2-ol (1.3 g, 10 mmol) and imidazole (1.7 g, 
25 mmol, 2.5 equiv.) in DMF (2.5 mL) was added tert-butyldimethylsilyl chloride (1.8 g, 12 
mmol, 1.2 equiv.) at room temperature, and the reaction medium was stirred overnight. Water 
(20 mL) was added and the mixture was extracted with ethyl acetate (3 x 20 mL). The 
combined organic extracts were washed with brine, dried over Na2SO4 and evaporated under 
reduced pressure. The crude material was purified by column chromatography on silica gel 
with pentane/diethyl ether (100:0 to 80:20) as eluent to afford pure 5-(((tert-
butyldimethylsilyl)oxy)methyl)pyridin-2-ol (1.3 g, 54%). 1H-NMR (400 MHz, DMSO-d6): δ 
11.36 (s, 1H), 7.31 (dd, 1H, J = 9.4 Hz, J = 2.7 Hz), 7.20 (m, 1H), 6.27 (d, 1H, J = 9.4 Hz), 
4.36 (s, 2H), 0.81 (s, 9H), 0.00 (s, 6H) ppm. 13C-NMR (101 MHz, DMSO-d6): δ 162.5, 141.3, 
133.0, 120.4, 118.2, 61.8, 26.3, 18.4, -4.7 ppm. HRMS (ESI) calcd for C12H22NO2Si [M+H]+: 
240.142. Found: 240.141. 
 
To a vigorously stirred solution of 5-(((tert-butyldimethylsilyl)oxy)methyl)pyridin-2-ol (0.48 
g , 2 mmol) in acetonitrile (4 mL) at room temperature was added a 6M aqueous solution of 
potassium hydroxide (4 mL). Difluoromethyltriflate (0.76 mL, 6 mmol, 3 equiv.) was added 
dropwise to the reaction mixture which was maintained at room temperature by means of a 
water bath (the reaction is exothermic), and the medium was stirred for 30 min. The mixture 
was diluted with water (20 mL) and extracted with diethyl ether (2 x 10 mL) and ethyl acetate 
(3 x 10 mL). The combined organic layers were dried over Na2SO4, filtered and evaporated 
under reduced pressure. The crude material was purified by column chromatography on silica 
gel with pentane/diethyl ether (100:0 to 90:10) as eluent to afford the pure title compound 13 
(0.40 g, 70%). 1H-NMR (400 MHz, CDCl3): δ 8.02 (m, 1H), 7.59 (dd, 1H, J = 8.1 Hz, J = 
2.5 Hz), 7.35 (t, 1H, J = 73.1 Hz), 6.73 (d, 1H, J = 8.4 Hz), 4.60 (s, 2H), 0.82 (s, 9H), 0.00 (s, 
6H) ppm. 13C-NMR (101 MHz, CDCl3): δ 158.3, 144.8, 138.5, 133.2, 114.1 (t, JC-F = 255.4 
Hz), 111.1, 62.2, 25.9, 18.3, -5.3 ppm. 19F-NMR (376 MHz, CDCl3): δ -88.6 (d, 2F, J = 72.9 
Hz) ppm. HRMS (ESI) calcd for C13H22F2NO2Si [M+H]+: 290.139. Found: 290.138. 
 
 5-(Chloromethyl)-2-(difluoromethoxy)pyridine (14).  
To a stirred solution of 5-(((tert- butyldimethylsilyl)oxy)methyl)-2-(difluoromethoxy)pyridine 
13 (1.4 g, 5 mmol) in THF (10 mL) was added a solution of TBAF (1.0 M solution in THF, 
10 mmol, 2 equiv.) at room temperature, and the mixture was stirred for 4 h. The reaction was 
quenched with saturated ammonium chloride and brine, and extracted with ethyl acetate (3x 
20 mL). The combined organic layers were dried over Na2SO4, filtered and evaporated under 
reduced pressure. The crude material was purified by column chromatography on silica gel 
with ethyl acetate/pentane (60:40) as eluent to afford pure (6-(difluoromethoxy)pyridin-3-
yl)methanol (761 mg, 87%). 1H-NMR (400 MHz, CDCl3): δ 8.15 (d, 1H, J = 2.5 Hz), 7.76 
(dd, 1H, J = 8.5 Hz, J = 2.5 Hz), 7.45 (t, 1H, J = 73.7 Hz), 6.90 (d, 1H, J = 8.5 Hz), 4.68 (m, 
2H), 2.04 (m, 1H) ppm. 13C-NMR (101 MHz, CDCl3): δ 158.7, 145.6, 139.4, 132.5, 114.1 (t, 
JC-F = 253.9 Hz), 111.4, 62.1 ppm. 19F-NMR (376 MHz, CDCl3): δ -88.7 (d, 2F, J = 73.5 Hz) 
ppm. HRMS (ESI) calcd for C7H8F2NO2 [M+H]+: 176.0518. Found: 176.0530. 
 
To a stirred solution of thionyl chloride (0.16 mL, 2.2 mmol, 1.1 equiv.) in toluene (1 mL) at 
room temperature was added dropwise a solution of (6-(difluoromethoxy)pyridin-3-
yl)methanol (0.35 g, 2 mmol) in toluene (2 mL). After 1 h at room temperature, vacuum was 
applied leading to the pure title compound 14 (0.34 g, 89%) without further purification. 1H-
NMR (400 MHz, CDCl3): δ 8.18 (d, 1H, J = 2.6 Hz), 7.78 (dd, 1H, J = 8.5 Hz, J = 2.6 Hz), 
7.46 (t, 1H, J = 72.8 Hz), 6.92 (d, 1H, J = 8.5 Hz), 4.56 (s, 2H) ppm. 13C-NMR (101 MHz, 
CDCl3): δ 158.9, 146.7, 140.6, 129.8, 114.0 (t, JC-F = 256.7 Hz), 111.4, 42.5 ppm. 19F-NMR 
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(376 MHz, CDCl3): δ -89.1 (d, 2F, J = 72.5 Hz) ppm. HRMS (ESI) calcd for C7H7ClF2NO 
[M+H]+: 194.018. Found: 194.018. 
 
 N-(1-((6-(Difluoromethoxy)pyridin-3-yl)methyl)-4,5-dihydro-1H-imidazol-2-
yl)nitramide (15) 
5-(Chloromethyl)-2-(difluoromethoxy)pyridine 14 (0.13 g, 0.69 mmol, 0.90 equiv.) was 
added dropwise to a solution of 4,5-dihydro-N-nitro-1H-imidazol-2-amine (0.10 g, 0.76 
mmol, 1 equiv.), potassium carbonate (0.10 g, 0.73 mmol, 0.96 equiv.) and caesium chloride 
(5.0 mg, 0.030 mmol, 0.03 equiv.) in acetonitrile (5 mL) at room temperature. The reaction 
mixture was stirred 5 hours at room temperature. It was then filtrated and the solvent was 
distilled off. The crude product was purified by HPLC on reverse phase with 
water/acetonitrile gradient, which afforded 15 (163.9 mg, 74%); 1H (DMSO-d6, 150 MHz): δ 
3.47 (m, 2H, CH2), 3.62 (m, 2H, CH2), 4.45 (s, 2H, CH2), 7.10 (d, 2H, C-H, Py, J = 8.4 Hz), 
7.70 (t, 1H, OCHF2, JC-F = 72.8 Hz), 7.86 (dd, 1H, C-H, Py, J = 8.4 Hz, J = 2.5 Hz), 8.22 (d, 
1H, C-H, Py, J = 2.5 Hz); 8.96 (s, 1H, NH); 13C NMR (proton-decoupled) (DMSO-d6, 150 
MHz): δ 41.7, 44.6, 45.1 (CH2), 111.5 (C-H, Ph), 114.9 (OCHF2), 128.9 (C, Ph), 141.0, 
146.7 (C-H, Ph), 158.1 (C-O, Ph), 160.5 (C=N); 19F NMR (DMSO-d6, 566 MHz): δ = -86.8 
(d, 2F, J = 72.9 Hz) ppm. HRMS (ESI) calcd for C10H12F2N5O3 [M+H]+: 288.0908. Found: 
288.0917. 
 
 N-(3-((6-(Difluoromethoxy)pyridin-3-yl)methyl)thiazolidin-2-
ylidene)cyanamide (16) 
5-(Chloromethyl)-2-(difluoromethoxy)pyridine 14 (0.13 g, 0.69 mmol, 0.90 equiv.) was 
added dropwise to a solution of N-(4,5-dihydro-2-thiazolyl)cyanamide (98 mg, 0.76 mmol, 1 
equiv.), potassium carbonate (0.10 g, 0.73 mmol, 0.96 equiv.) and caesium chloride (5.0 mg, 
0.030 mmol, 0.03 equiv.) in acetonitrile (5 mL) at room temperature. The reaction mixture 
was stirred 5 hours at room temperature. It was then filtrated and the solvent was distilled off. 
The crude product was purified by HPLC on reverse phase with water/acetonitrile gradient, 
which afforded of 16 (158.5 mg, 72%); 1H (DMSO-d6, 150 MHz): δ 3.49 (m, 2H, CH2), 3.90 
(m, 2H, CH2), 4.62 (s, 2H, CH2), 7.11 (d, 2H, C-H, Py, J = 8.4 Hz), 7.71 (t, 1H, OCHF2, JC-F = 
72.7 Hz), 7.85 (dd, 1H, C-H, Py, J = 8.4 Hz, J = 2.5 Hz), 8.23 (d, 1H, C-H, Py, J = 2.5 Hz); 
13C NMR (proton-decoupled) (DMSO-d6, 150 MHz): δ 27.5, 46.4, 52.9 (CH2), 111.5 (C-H, 
Py), 114.9 (OCHF2), 128.0 (C, Py), 141.2, 147.0 (C-H, Py), 158.2 (C-O, Py), 174.8 (C=N); 
19F NMR (DMSO-d6, 566 MHz): δ = -86.88 (d, 2F, J = 72.8 Hz) ppm. HRMS (ESI) calcd for 
C11H11F2N4OS [M+H]+: 285.0622. Found: 285.0618. 
 
 Receptor binding studies (pI50-values in vitro) 
 
Radioligand [3H]imidacloprid displacement studies were conducted according to established 
protocols by using membranes isolated from frozen (−80 °C) housefly (Musca domestica L.) 
heads.[33, 34] Briefly, 5 g heads were homogenised in 100 mL of 0.1 MK-phosphate buffer, 
pH 7.4, 320 mM of sucrose and 1 mM of EDTA using an Ultra Turrax at 4 °C. After 
centrifugation for 
15 min at 1200 × g and 4 °C, the pellet was resuspended and centrifuged again. Both 
supernatants were combined and filtered through Miracloth, and the filtrate was subsequently 
centrifuged at 105.000 × g for 60 min at 4 °C. The resulting pellet was resuspended in buffer 
and adjusted to approximately 0.5 mg protein mL−1. The assay was conducted in a total 
volume of 1 mL, 
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consisting of 850 µL of homogenate and 50 µL of [3H]imidacloprid (25.000 dpm; 1.406 GBq 
µmol−1) in 0.1 MK-phosphate buffer, pH 7.4, containing 1 g L−1 of BSA and 5% ethanol 
(0.25% final concentration). After 5 min, different concentrations of the F3CO- and F2HCO-
analogues of imidacloprid (8, 15) and thiacloprid (9, 16) were added (1000, 100, 10, 3, 1, 0.3, 
0.1 and 0.01 nM, containing up to 0.1% DMSO). After incubation for 60 min at 22 °C while 
shaking, the samples were filtered through prewetted Whatman GF/C glass fibre filters, 
followed by two rinseswith 3 mL of ice-cold 0.1 MK-phosphate buffer (pH 7.4). 
Subsequently, the filters were dried (55 °C, 40 min), and 3.5 mL of scintillation cocktail was 
added. After 16 h at room temperature, the samples were subjected to liquid scintillation 
counting. 
 
Myzus persicae – spray test (in vivo) 
Solvent: 78.0 parts by weight acetone 
 1.5 parts by weight N,N-dimethylformamide 
Emulsifier: alkylarylpolyglycol ether 
To produce a suitable preparation of active compound, 1 part by weight of the F3CO- and 
F2HCO-analogues of imidacloprid (8, 15) and thiacloprid (9, 16) is mixed with the stated 
amount of solvents and is diluted with water, containing an emulsifier concentration of 1000 
ppm, to the desired concentration. Further test concentrations are prepared by dilution with 
emulsifier containing water.  
Chinese cabbage (Brassica pekinensis) leaf disks infected with all instars of the green peach 
aphid (Myzus persicae), are sprayed with a preparation of the active ingredient of the desired 
concentration. 
After 5-6 days mortality in % is determined. 100 % means all aphids have been killed and 0 
% means none of the aphids have been killed. 
In this test, for example, the compounds 8 and 16 from the preparation examples showed 
good activity of 100 % at an application rate of 500 g ha-1 and the compounds 9 and 15 from 
the preparation examples showed good activity of 100 % at an application rate of 100 g ha-1. 
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